header-image

Navigating ATMP Development - Online Training Recording

Seminar-Nr. 22629

Referent:innen

Dr Sabine Hauck

Dr Sabine Hauck

dequra pharma consult hauck, Chair of ECA ATMP Interest Group

Dr Katja Aschermann

Dr Katja Aschermann

Astator

Dr Roland Pach

Dr Roland Pach

Roche

Prof Dr Sven Stegemann

Prof Dr Sven Stegemann

DWI Leibniz-Institut für Interaktive Materialien e.V.

Dr Rainer Gnibl

Dr Rainer Gnibl

GMP Inspector

Zielsetzung

The aim of the training is to provide participants with fundamental, practical knowledge along the entire ATMP development process - from preclinical research to clinical application and GMP-compliant manufacturing. The content covers regulatory requirements (EMA, ICH, GMP), CMC strategies, process development, analytics, validation and quality assurance. Participants will learn how to overcome typical challenges, avoid typical mistakes and efficiently integrate regulatory and scientific requirements into everyday development work.

Hintergrund

The development of advanced therapy medicinal products (ATMPs), including gene therapies, cell therapies, and tissue-engineered products, is characterized by a high level of scientific, technical, and regulatory complexity. These innovative medicinal products must comply with stringent and ever-changing regulatory requirements, as set out in various European and international guidance documents. Examples include the EMA Guideline on “Quality, non-clinical and clinical aspects of gene therapy medicinal products” (EMA/CAT/80183/2014), The guideline on “Human cell-based medicinal Products” (EMEA/CHMP/410869/2006), EudraLex Volume 4 Part IV for ATMPs and cross-cutting ICH guidelines, such as ICH Q8–Q10 (quality by design and pharmaceutical quality systems) and ICH Q14 (analytical procedure development).

The transition from preclinical research to first-in-human trials and later market authorization – often referred to as the “bench to bedside” process – requires a development strategy that integrates regulatory foresight, robust CMC (Chemistry, Manufacturing and Control) planning, and comprehensive quality oversight from the earliest stages. Particular challenges in ATMP development include raw material qualification, platform-independent process validation, aseptic processing strategies, and the implementation of analytical approaches in accordance with ICH Q14 principles. Upscaling and tech transfer into GMP-compliant manufacturing environments require strategic foresight and alignment with GMP for ATMPs (EudraLex Vol. 4 Part IV).

This training course provides participants with a practice-oriented understanding of the end-to-end ATMP development process. It offers in-depth insights into regulatory expectations, process and analytical development, validation strategies, and the specific responsibilities of the Qualified Person (QP) under EU legislation. Participants will develop confidence in applying risk-based approaches (as outlined in ICH Q9) and addressing critical regulatory interfaces during development and scale-up. The course provides professionals with the strategies and regulatory expertise needed to successfully implement, ensure GMP compliance and ultimately authorize ATMPs in a dynamic and highly regulated environment.

Zielgruppe

This training is aimed at specialists and managers from development, production, quality assurance, regulatory affairs and project management, especially pharmaceutical companies focusing on ATMPs, as well as qualified persons and representatives of authorities.

Technical Details:

To participate in an on demand training course or webinar, you do not need any software. The recordings are made available via a streaming server. In general, the recording is provided in MP4 format, which any PC (Microsoft Windows, Apple IOS) or tablet can easily display.

Timing and Duration:
When you register for the on demand Training course or webinar you can decide at what date you want to follow the training course online. For a 1-day training course you will have 2 days in which the stream is available (for 2-day training course 3 days and for a 3-day training course 4 days). Within in this timeframe you can start & stop the stream according to your needs.
In time before the scheduled date (your desired date) you will receive an e-mail from us with a link for direct participation as well as your log-in data.

Please be aware: The recording does not include the Q & A sessions.

Training Course Documentation and Certificate:
The presentation will be made available as PDF-files via download during the online training course. After the successful completion of the online training, you are able to download the certificate of attendance.

Programm

From Phase 1 to Scale-up: GMP Requirements for ATMPs
Sabine Hauck
  • Regulatory landscape: EMA guidance, ICH and GMP 
  • Stability program
  • Challenges of IMPs and IMPD
Raw Material Selection in ATMP Development
Katja Aschermann
  • Why it matters
  • Regulatory requirements
  • Selection criteria
CMC Strategies for ATMPs: Process Development and Quality Oversight
Roland Pach
  • Quality oversight & regulatory
  • Addressing specific challenges in ATMP CMC
  • AAV case study
Qualification & Validation Challenges in ATMP Manufacturing Systems
Rainer Gnibl
  • Cleanroom qualification
  • Basics of process and cleaning Validation
  • Aseptic validation (media fill)
  • Validation life cycle
Analytical Development for ATMPs -  Implementing ICH Q14 in Practice
Katja Aschermann
  • Approaches for analytical procedure development
  • Enhanced approach in theory
  • Practical examples
Applying QbD principles in ATMP development – Challenges and Opportunities
Sven Stegemann
  • QbD (ICH Q8) in pharmaceutical product development to assure reproducibility by product and process understanding
  • Differences and communalities of small molecules, biologics and ATMP products
  • Potential of QbD to improve ATMP processing and control for point-of-care manufacturing
The QP’s Role in ATMP Development and Lot Release Under EU Law
Sabine Hauck
  • GMP requirements for the QP role
  • Managing special cases specific to ATMPs
  • Communication between QP, manufacturing, and clinical teams
Towards “First-in-Human” – Considerations for early Clinical Trial Design of ATMP
Sven Stegemann
  • Preclinical studies and data to support the appropriate design for the “first-in-human” clinical Trial
  • Traditional and evolving clinical study designs to proof safety and efficacy
  • Prerequisites and considerations to enter into a “first-in-human” trial
Scaling Up ATMP Manufacturing
Roland Pach
  • Key aspects of scaling up ATMP
  • Examples & challenges of scaling up strategies
  • AAV case study
How to handle Deviations
Katja Aschermann
  • What is a deviation and how to evaluate criticality
  • Core characteristics of an efficient deviation handling system
  •  Root cause investigations
Change Control in agile ATMP Development Environments
Katja Aschermann
  • Managing change control throughout the product lifecycle
  •  The change control process in an agile environment
Risk-based approaches: How to do it right
Sabine Hauck
  • Understanding the Risk-Based Approach in development of ATMPs
  • Risk assessment tools and the link to ICH Q9
  •  Examples for implementation of risk-based approach
Bridging Development and GMP
Sabine Hauck
  • Common pitfalls in ATMP tech transfer between R&D and GMP
  • Establishing robust documentation and traceability early on
  • Role of development reports, knowledge management, and comparability data
Recording from 7/8 October 2025
Duration of Recording: 11 h

ECA-Member*: € 1890,-
Regular Fee*: € 2090,-
EU/GMP Inspectorates*: € 1045,-
APIC Member Discount*: € 1990,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.

Frau mit Headset
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Kurzweilig, informativ“
Behrendt, Christian, IOI Oleo GmbH

„Austausch zwischen Teilnehmern & Vortragenden sorgt für Anstöße & Optimierungsmöglichkeiten im eigenen Unternehmen! Praxisnahe Beispiele veranschaulichen und vertiefen die Theorie sehr gut“
Marina Maier, CHEPLAPHARM Arzneimittel GmbH

Abweichungen und CAPA (QS 12)
November 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular